BioGliph, a Berkeley, CA-based startup biotech software company, received a minority investment from Dotmatics.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Fernando Garces, BioGlyph is developing technology to visually illustrate, register, and model biologic molecules including, specifically, multispecific antibodies (MsAbs) With a focus on innovative therapeutic applications, the company leverages advanced technologies to design and produce highly specific antibodies that address complex biological challenges.
Dotmatics is a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and applications are used by more than 2 million scientists and 10,000 customers. Dotmatics, which employs a global team of more than 800 people, has made 14 acquisitions since 2017. The company’s principal office is in Boston, with 14 offices and R&D teams located around the world.
Dotmatics is backed by Insight Partners.
FinSMEs
07/08/2024